Lucid Diagnostics Inc. Cash Flow Statement
LUCD|4 years of annual SEC 10-K data (FY2021-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$33M
FY2024
Free Cash Flow
N/A
FY2024
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2024
Lucid Diagnostics Inc. used $33M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Net Income | -$52.7M | -$56.2M | -$28.1M | -$8.3M |
| Depreciation & Amortization | $2.5M | $1.9M | $4.0K | $4.0K |
| Operating Cash Flow | -$32.8M | -$29.7M | -$17.7M | -$5.6M |
| Capital Expenditures | - | $3.2M | $3.2M | $862.0K |
| Free Cash Flow | - | -$32.9M | -$20.9M | -$6.5M |
| FCF Margin | - | -8722.8% | -4173.6% | -1298.2% |